Cassava Sciences settles with SEC for $40M over skewed Alzheimer’s drug data
By 
Adrianne Appel2024-09-27T18:00:00
A former Alzheimer’s researcher manipulated the results of a Cassava Sciences drug, with the pharmaceutical company and its former chief executive reaching a $40 million settlement with the Securities and Exchange Commission (SEC) over allegedly misleading the public.
Prior to 2020, researcher Hoau-Yan Wang, associate medical professor at City University of New York Medical School, embarked on a purported blind clinical trial of the experimental Alzheimer’s drug Simufilam.
Wang, who had a financial stake in the outcome of the drug trial, found out which patients had taken the drug in a third of cases and skewed the data to make the drug look dramatically more effective, the SEC alleged in it order against Wang.
Related articles
-
News BriefTeva Pharma to pay $450M to settle kickback, price-fixing allegations
Generic drug giant Teva Pharmaceuticals has agreed to pay $450 million to settle two cases brought by the Department of Justice (DOJ), including one alleging that co-pays it made on behalf of Medicare patients constituted illegal kickbacks, and a second action for alleged generic drug price fixing.
-
ArticleDOJ probe into shadowy underworld of short selling ‘long overdue’
A Department of Justice criminal investigation into illegal short selling is just the latest indication these schemes demand greater scrutiny that chief compliance officers and in-house counsel can no longer afford to ignore.
-
ArticleS&T AG orders Deloitte audit of short seller allegations
Austrian technology company S&T AG has ordered a forensic audit of its corporate structure and several recent acquisitions in response to allegations made by short seller Viceroy Research.
More from Regulatory Enforcement
-
News BriefDOJ targets $14.6B in health care fraud with focus on transnational crime
Emerging enforcement priorities of the U.S. Department of Justice’s health care fraud division align with the Trump administration’s emphasis on prosecuting transnational criminal organizations and ending opioid trafficking.
-
News BriefFTC raises antitrust concerns over $1.57B Circle K deal, orders divestitures
Since President Donald Trump took office, the U.S. Federal Trade Commission has yet to keep up the level of enforcement it had under previous chair Lina Khan. The agency, however, returned to antitrust action in the case of fuel stations, just in time for the July 4th holiday.
-
News BriefJudge reinstates fired CPSC commissioners in latest battle over government cuts
In May, three commissioners for the Consumer Product Safety Commission were abruptly fired by President Donald Trump and sued for their jobs shortly after. A federal judge has ruled that the commissioners should be reinstated, although it’s unclear whether that ruling may itself be reversed.